贝利尤单抗对自身免疫模型大鼠甲状腺激素水平的影响  

Effects of belimumab on thyroid hormone levels in autoimmune model rats

作　　者：王小润 徐佳漫 郑淑芬 刘菊娥[1] 钟诗龙[1] WANG Xiao-run;XU Jia-man;ZHENG Shu-fen;LIU Ju-e;ZHONG Shi-long(Department of Pharmacy,Guangdong Provincial People's Hospital,Guangdong Academy of Medical Science,Guangzhou 510000,Guangdong Province,China;Guangdong Pharmaceutical University,Guangzhou 510000,Guangdong Province,China)

机构地区：[1]广东省人民医院、广东省医学科学院药学部,广东广州510000 [2]广东药科大学,广东广州510000

出　　处：《中国临床药理学杂志》2021年第17期2328-2330,共3页The Chinese Journal of Clinical Pharmacology

基　　金：国家自然科学基金面上基金资助项目(81872934)。

摘　　要：目的探究贝利尤单抗对自身免疫模型大鼠甲状腺激素水平的影响。方法给予左甲状腺素钠模拟体内高甲状腺激素水平,建立甲状腺功能亢进模型。按照体重将SD雌性大鼠随机分为3组:正常组、模型组和实验组,每组10只。正常组灌胃给予生理盐水,模型组灌胃给予左甲状腺素钠0.75μg·g^(-1),均持续29 d;实验组在造模期间的第15,29天皮下注射贝利尤单抗10μg·g^(-1)。第30天,检测外周血白细胞(WBC)、中性粒细胞的绝对值(NEU)和淋巴细胞的绝对值(LYM),并检测甲状腺功能三项,包括游离甲状腺素3(FT3)、游离甲状腺素4(FT4)和促甲状腺激素(TSH)的水平。结果正常组、模型组和实验组的FT3分别为(4.71±0.36),(10.22±0.52)和(16.53±0.58)pmol·L^(-1);FT4分别为(21.75±2.05),(44.95±3.19)和(62.11±4.54)pmol·L^(-1);TSH分别为(5.80±0.60),(11.30±0.60)和(7.60±0.08) mu·mL^(-1);WBC分别为(4.53±0.17),(4.60±0.56)和(1.72±0.37)×10^(9)/L;NEU分别为(0.32±0.04),(0.37±0.06)和(1.11±0.23)×10^(9)/L;LYM分别为(3.64±0.15),(3.96±0.51)和(0.43±0.10)×10^(9)/L。上述指标:模型组与正常组相比,或实验组与模型相比,差异均有统计学意义(均P<0.05)。结论贝利尤单抗可使血液中甲状腺激素水平显著升高,这或可用于治疗桥本氏甲状腺炎所致的甲状腺功能低下。Objective To investigate the effects of Beliliumab on thyroid hormone levels in autoimmune model rats.MethodsThe hyperthyroidism model was established by giving levothyroxine sodium to simulate the high thyroid hormone level in vivo.Female SD rats were randomly divided into 3 groups according to weight:Normal group (was given normal saline by gavage for 29 d),model group (was given 0.75μg·g^(-1)levothyroxine sodium intragastrically for 29 d);on the 15th and29th day of modeling period,experimental group was given 10μg·g^(-1)Belimumab powder,with 10 rats in each group.At the 30th day and blood samples were collected to detect the contents of white blood cell(WBC),neutrophil granulocyte (Neu) and lymphocyte (Lymphocyte)in peripheral blood,and the intensity of variation of the three thyroid functions including free thyroxine 3 (FT3),free thyroxine 4 (FT4) and thyroid stimulating hormone (TSH) were detected.Results The FT3 in normal group,model group and experimental group were (4.71±0.36),(10.22±0.52) and (16.53±0.58) pmol·L^(-1)respectively;FT4 in the 3 groups were (21.75±2.05),(44.95±3.19) and (62.11±4.54) pmol·L^(-1);TSH in the 3 groups were (5.80±0.60),(11.30±0.60) and(7.60±0.08) mu·m L^(-1);WBC in the 3 groups were (4.53±0.17),(4.60±0.56) and (1.72±0.37)×10^(9)/L respectively;Neu in the 3 groups were (0.32±0.04),(0.37±0.06) and (1.11±0.23)×10^(9)/L;LYM in the 3groups were (3.64±0.15),(3.96±0.51) and (0.43±0.10)×10^(9)/L.The above indicators showed statistically significant differences between the model group and the normal group,or between the experimental group and the model(all P<0.05).Conclusion Beliliumab can significantly increase the level of thyroid hormone in blood,which may be used to treat hypothyroidism caused by Hashimoto’s thyroiditis.

关 键 词：贝利尤单抗 左甲状腺素钠 自身免疫性甲状腺疾病 桥本氏甲状腺炎 

分 类 号：R97[医药卫生—药品]